AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Prenetics Global Limited

$23.47 +$7.69 (+48.73%)
NASDAQ · 11 Sep 2026 20:00 UTC
Previous Close
$23.66
Day Range
$23.03$24.14
Year Range
$9.28$27.24
Market Cap
399M
AVG Volume
241.37K
Trailing/Forward PE
-5.64/-
PEG ratio
0.11
Dividend Yield
-
Next Earnings Date
2026-11-09
Primary Exchange
NASDAQUS
Revenue (USD)
020M40M60M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PRE Revenue (USD) by quarter
PeriodRevenue (USD)
26 Q246.49M
26 Q135.95M
25 Q436.56M
25 Q323.55M
25 Q217.68M
25 Q117.31M
24 Q410.49M
24 Q37.78M
24 Q25.94M
24 Q16.41M
Net Income (USD)
-30M-20M-10M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PRE Net Income (USD) by quarter
PeriodNet Income (USD)
26 Q2-8.98M
26 Q1-23.1M
25 Q4-28.11M
25 Q3-7.41M
25 Q2-12.41M
25 Q1-10.39M
24 Q4-16.34M
24 Q3-10.67M
24 Q2-10.72M
24 Q1-8.57M
Operating Income (USD)
-30M-20M-10M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PRE Operating Income (USD) by quarter
PeriodOperating Income (USD)
26 Q2-21.92M
26 Q1-9.71M
25 Q4-12.39M
25 Q3-6.16M
25 Q2-10.06M
25 Q1-10.63M
24 Q4-16.57M
24 Q3-11.81M
24 Q2-10.61M
24 Q1-9.16M
EBITDA (USD)
-30M-20M-10M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PRE EBITDA (USD) by quarter
PeriodEBITDA (USD)
26 Q2-21.73M
26 Q1-9.52M
25 Q4-24.54M
25 Q3-6.72M
25 Q2-10.89M
25 Q1-11M
24 Q4-24.89M
24 Q3-10.93M
24 Q2-10M
24 Q1-9.29M
Cash Flows (USD)
-30M-20M-10M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PRE Cash Flows (USD) by quarter
PeriodCash Flows (USD)
26 Q20
26 Q1-12.12M
25 Q4-22.02M
25 Q30
25 Q20
25 Q10
24 Q40
24 Q30
24 Q20
24 Q10
EPS (USD)
-2-1.5-1-0.5024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PRE EPS (USD) by quarter
PeriodEPS (USD)
26 Q2-0.52
26 Q1-1.36
25 Q4-1.75
25 Q3-0.53
25 Q2-0.94
25 Q1-0.8
24 Q4-1.29
24 Q3-0.84
24 Q2-0.88
24 Q1-0.7
Expenses (USD)
-20M020M40M60MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PRE Expenses (USD) by quarter
PeriodExpenses (USD)
26 Q236.67M
26 Q132.99M
25 Q429.52M
25 Q320.58M
25 Q217.16M
25 Q118.29M
24 Q421.76M
24 Q315.71M
24 Q215.13M
24 Q113.69M
Cash & Debt (USD)
050M100M150MCashLong Term DebtShort Term Debt24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PRE Cash & Debt (USD) by quarter
PeriodCash & Debt (USD)
26 Q2109.39M
26 Q1106.03M
25 Q461.49M
25 Q323.73M
25 Q227.71M
25 Q158.53M
24 Q462.81M
24 Q342.83M
24 Q252.1M
24 Q165.55M
Debt ratios
012324 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PRE Debt ratios by quarter
PeriodDebt ratios
26 Q21.74
26 Q12.04
25 Q41.12
25 Q30.4
25 Q20.44
25 Q10.94
24 Q41.03
24 Q30.89
24 Q21.18
24 Q11.39
Margins
0%20%40%60%80%24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PRE Margins by quarter
PeriodMargins
26 Q264.97%
26 Q164.76%
25 Q459.47%
25 Q359.54%
25 Q241.23%
25 Q142.41%
24 Q437.2%
24 Q350.75%
24 Q263.42%
24 Q158.97%
Return on Capital
-20%-15%-10%-5%0%24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PRE Return on Capital by quarter
PeriodReturn on Capital
26 Q2-9.67%
26 Q1-19.09%
25 Q4-16.11%
25 Q3-4.6%
25 Q2-8.22%
25 Q1-6.45%
24 Q4-9.54%
24 Q3-5.93%
24 Q2-5.61%
24 Q1-4.23%
Shares Outstanding
05M10M15M20M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PRE Shares Outstanding by quarter
PeriodShares Outstanding
26 Q217.27M
26 Q116.98M
25 Q416.03M
25 Q313.9M
25 Q213.25M
25 Q113M
24 Q412.71M
24 Q312.71M
24 Q212.22M
24 Q112.22M
Dividends (USD)
00.20.40.60.8Nov 13Feb 14May 14Aug 14Nov 14Feb 15May 15Aug 15Nov 15Feb 16
PRE Dividends (USD) by quarter
PeriodDividends (USD)
Feb 160.7
Nov 150.7
Aug 150.7
May 150.7
Feb 150.7
Nov 140.67
Aug 140.67
May 140.67
Feb 140.67
Nov 130.64
Employee Count
05001K1.5K20222022202320242025
PRE Employee Count by quarter
PeriodEmployee Count
202598
2024285
2023324
2022400
20221.16K
Book Value Per Share (USD)
0510152024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PRE Book Value Per Share (USD) by quarter
PeriodBook Value Per Share (USD)
26 Q25.38
26 Q17.13
25 Q410.88
25 Q311.6
25 Q211.39
25 Q112.39
24 Q413.49
24 Q314.18
24 Q215.63
24 Q116.6
Total Assets (USD)
0100M200M300M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PRE Total Assets (USD) by quarter
PeriodTotal Assets (USD)
26 Q2153.66M
26 Q1175.3M
25 Q4203.52M
25 Q3196.51M
25 Q2199.11M
25 Q1204.01M
24 Q4213.57M
24 Q3235.77M
24 Q2233.31M
24 Q1243.59M
PE Ratio
706708710712714med 709.77Jul 21Jul 21Aug 21Aug 21Aug 21Aug 21
PRE PE Ratio by quarter
PeriodPE Ratio
Aug 21706.92
Aug 21706.92
Aug 21711.35
Aug 21710.4
Jul 21709.13
Jul 21712.8
Free Cash Flow Yield
-15%-10%-5%0%med 0%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
PRE Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-8.43%
Sep 26-7.77%
Aug 26-7.68%
Aug 26-9.79%
Aug 26-10.18%
Aug 26-11.01%
Jul 26-10.79%
Jul 26-10.73%
Jul 26-10.99%
Jul 26-11.26%
Jul 26-11.88%
Jun 26-10.68%
Jun 26-9.81%
Jun 26-9.29%
Jun 26-6.91%
May 26-6.51%
May 26-8.19%
May 26-8.8%
May 26-8.5%
May 26-8.07%
Apr 26-7.49%
Apr 26-7.7%
Apr 26-7.75%
Apr 26-6.98%
Mar 26-6.7%
Mar 26-7%
Mar 26-6.63%
Mar 26-7.71%
Feb 26-8.12%
Feb 26-8.05%
Feb 260%
Feb 260%
Jan 260%
Jan 260%
Jan 260%
Jan 260%
Jan 260%
Dec 250%
Dec 250%
Dec 250%
Dec 250%
Nov 250%
Nov 250%
Nov 250%
Nov 250%
Oct 250%
Oct 250%
Oct 250%
Oct 250%
Oct 250%
Sep 250%
Sep 250%
Sep 250%
Sep 250%
Aug 250%
Aug 250%
Aug 250%
Aug 250%
Aug 250%
Jul 250%
Jul 250%
Jul 250%
Jul 250%
Jun 250%
Jun 250%
Jun 250%
Jun 250%
May 250%
May 250%
May 250%
May 250%
May 250%
Apr 250%
Apr 250%
Apr 250%
Apr 250%
Mar 250%
Mar 250%
Mar 250%
Mar 250%
Feb 250%
Feb 250%
Feb 250%
Feb 250%
Jan 250%
Jan 250%
Jan 250%
Jan 250%
Jan 250%
Dec 240%
Dec 240%
Dec 240%
Dec 240%
Nov 240%
Nov 240%
Nov 240%
Nov 240%
Nov 240%
Oct 240%
Oct 240%
Price to Sales
12345med 2.86Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
PRE Price to Sales by quarter
PeriodPrice to Sales
Sep 262.84
Sep 263.08
Aug 263.12
Aug 262.45
Aug 262.95
Aug 262.73
Jul 262.78
Jul 262.8
Jul 262.73
Jul 262.67
Jul 262.53
Jun 262.81
Jun 263.06
Jun 263.23
Jun 263.35
May 263.56
May 262.83
May 262.63
May 262.72
May 262.87
Apr 263.09
Apr 263.01
Apr 262.99
Apr 263.32
Mar 263.46
Mar 263.31
Mar 263.49
Mar 263
Feb 262.85
Feb 262.87
Feb 264.42
Feb 263.87
Jan 263.84
Jan 263.71
Jan 263.16
Jan 263.13
Jan 263.18
Dec 253.4
Dec 253.52
Dec 252.99
Dec 252.82
Nov 252.93
Nov 252.55
Nov 252.46
Nov 253.07
Oct 253.69
Oct 254.17
Oct 253.73
Oct 253.45
Oct 253.55
Sep 253.13
Sep 252.98
Sep 252.5
Sep 252.53
Aug 252.39
Aug 252.27
Aug 253.15
Aug 253.08
Aug 253.32
Jul 253.34
Jul 253.28
Jul 253.27
Jul 253.32
Jun 253.52
Jun 253.72
Jun 252.91
Jun 253.45
May 253.86
May 254.28
May 252.61
May 252.24
May 252.2
Apr 252.5
Apr 252.01
Apr 251.8
Apr 251.89
Mar 252
Mar 252.03
Mar 252.26
Mar 252.38
Feb 252.46
Feb 252.67
Feb 252.71
Feb 252.5
Jan 252.63
Jan 252.76
Jan 252.83
Jan 252.72
Jan 252.83
Dec 242.85
Dec 242.83
Dec 242.97
Dec 242.58
Nov 242.24
Nov 242.4
Nov 242.44
Nov 242.5
Nov 242.51
Oct 242.53
Oct 242.77
EV/EBITDA
406080100med 97.15Jul 21Aug 21Sep 21Sep 21Oct 21Nov 21Nov 21
PRE EV/EBITDA by quarter
PeriodEV/EBITDA
Nov 2197.3
Nov 2197.35
Nov 2197.3
Nov 2197.39
Oct 2197.15
Oct 2197.15
Oct 2197.2
Oct 2197.1
Oct 2197.49
Sep 2197.49
Sep 2197.25
Sep 2196.48
Sep 2196.34
Aug 2149.86
Aug 2149.86
Aug 2150.16
Aug 2150.1
Jul 2150.01
Jul 2150.26
Price/Operating Cashflow
020406080med 12.43Apr 22Jun 22Aug 22Oct 22Dec 22Feb 23Apr 23
PRE Price/Operating Cashflow by quarter
PeriodPrice/Operating Cashflow
Apr 234
Apr 234.03
Apr 233.88
Apr 234.58
Mar 234.64
Mar 233.58
Mar 233.84
Mar 234.25
Mar 235.03
Feb 234.88
Feb 235.65
Feb 236.86
Feb 237.1
Jan 237.44
Jan 237.49
Jan 238.55
Jan 239.18
Dec 229.66
Dec 2210.15
Dec 2210.92
Dec 228.75
Dec 228.75
Nov 226.23
Nov 227.77
Nov 2210.29
Nov 2210.68
Oct 2210.99
Oct 2212.43
Oct 2212.36
Oct 2212.33
Sep 2212.94
Sep 2212.33
Sep 2212.43
Sep 2214.59
Sep 2213.46
Aug 2216.64
Aug 2216.64
Aug 2216.81
Aug 2216.98
Jul 2217.02
Jul 2217.02
Jul 2216.89
Jul 2217.15
Jul 2216.78
Jun 2217.87
Jun 2217.61
Jun 2219.02
Jun 2221.49
May 2221.83
May 2251.08
May 2271.66
May 2268.69
Apr 2268.97
Apr 2268.69
Apr 2268.76
Apr 2268.69
Apr 2268.21
Mar 2268.38
Mar 2268.62
Mar 2268.55
Mar 2268.62
Price to Book
0246med 1.07Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
PRE Price to Book by quarter
PeriodPrice to Book
Sep 264.36
Sep 264.73
Aug 264.79
Aug 263.75
Aug 262.77
Aug 262.56
Jul 262.62
Jul 262.63
Jul 262.57
Jul 262.51
Jul 262.38
Jun 262.64
Jun 262.88
Jun 263.04
Jun 261.82
May 261.94
May 261.54
May 261.43
May 261.48
May 261.56
Apr 261.68
Apr 261.64
Apr 261.63
Apr 261.81
Mar 261.88
Mar 261.8
Mar 261.9
Mar 261.64
Feb 261.55
Feb 261.57
Feb 261.89
Feb 261.66
Jan 261.65
Jan 261.59
Jan 261.36
Jan 261.34
Jan 261.36
Dec 251.46
Dec 251.51
Dec 251.28
Dec 251.21
Nov 251.25
Nov 251.09
Nov 251.05
Nov 251.08
Oct 251.3
Oct 251.47
Oct 251.32
Oct 251.22
Oct 251.25
Sep 251.1
Sep 251.05
Sep 250.88
Sep 250.65
Aug 250.61
Aug 250.59
Aug 250.56
Aug 250.55
Aug 250.59
Jul 250.6
Jul 250.59
Jul 250.59
Jul 250.59
Jun 250.63
Jun 250.66
Jun 250.52
Jun 250.62
May 250.69
May 250.76
May 250.47
May 250.4
May 250.39
Apr 250.35
Apr 250.28
Apr 250.25
Apr 250.27
Mar 250.28
Mar 250.29
Mar 250.32
Mar 250.34
Feb 250.35
Feb 250.38
Feb 250.38
Feb 250.35
Jan 250.37
Jan 250.39
Jan 250.4
Jan 250.38
Jan 250.4
Dec 240.4
Dec 240.4
Dec 240.42
Dec 240.36
Nov 240.32
Nov 240.28
Nov 240.29
Nov 240.29
Nov 240.3
Oct 240.3
Oct 240.33
Prenetics Global Limited
PRE
Stockpicker

Video analysis: PRE

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: PRE

Prenetics' IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results

globenewswire.com · 26 Aug 2026

Prenetics' IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results

Cumulative Personal Investment by Leadership Since November 2025 Reaches Approximately $3.75 Million NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading consumer health company and parent of the AI-native direct-to-consumer wellness brand IM8, co-founded by David Beckham, today announced that Danny Yeung, Chief Executive Officer, and Brian Rosin, Chief Financial Officer, completed open market purchases of the Company's ordinary shares during the period between August 20 and August 25, 2026, within the Company's open trading window following the release of second quarter 2026 financial results. The two executives acquired $1.0 million of shares.

Prenetics Global: Marketing Mastery The Key To Robust Revenue Growth

seekingalpha.com · 24 Aug 2026

Prenetics Global: Marketing Mastery The Key To Robust Revenue Growth

Prenetics Global Limited has achieved explosive growth, reaching 140,000 subscriptions in 20 months, driven by its IM8 supplement and AI-powered marketing. One of the keys to this growth is its marketing mastery, using A/B and multivariate testing to quickly identify the most effective advertising messages. A unique deal with General Catalyst enables PRE to finance up to 70% of customer acquisition costs without equity dilution or debt, amplifying marketing leverage.

Prenetics Global Limited (PRE) Q2 2026 Earnings Call Transcript

seekingalpha.com · 22 Aug 2026

Prenetics Global Limited (PRE) Q2 2026 Earnings Call Transcript

Prenetics Global Limited (PRE) Q2 2026 Earnings Call Transcript

Prenetics' IM8 Announces Two-Time Golden Globe-Nominated Actress and Producer Lily Collins as IM8 Global Ambassador and Shareholder in Multi-Year Partnership

globenewswire.com · 20 Aug 2026

Prenetics' IM8 Announces Two-Time Golden Globe-Nominated Actress and Producer Lily Collins as IM8 Global Ambassador and Shareholder in Multi-Year Partnership

— Lily is IM8's first Global Ambassador from film and television, extending a roster built in elite sport into global entertainment and culture — Lily brings a following of more than 33 million across social platforms and an engagement rate of approximately 5.9%, several times the benchmark for accounts of comparable scale — Partnership lands as Prenetics raises FY 2026 revenue guidance to $220+ million; Initiates FY 2027 revenue guidance of $400+ million — Joins an equity-aligned roster of David Beckham, Giannis Antetokounmpo, Aryna Sabalenka, Ollie Bearman, Jay Shetty and Inter Miami CF NEW YORK, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), the parent company of IM8, the premium health and longevity brand co-founded with David Beckham, today announced a multi-year global partnership with two-time Golden Globe-nominated actress and producer Lily Collins, star and executive producer of Netflix's Emily in Paris. Collins becomes a Global Ambassador of IM8 and a shareholder in Prenetics, demonstrating her long-term conviction in the brand and the Company.

Prenetics Global Q2 Earnings Call Highlights

marketbeat.com · 18 Aug 2026

Prenetics Global Q2 Earnings Call Highlights

Prenetics Global NASDAQ: PRE reported second-quarter revenue of $46.5 million, up 29% sequentially and about 3.9 times from a year earlier, as its IM8 supplement business continued to add subscribers and scale marketing spending. The company raised its full-year revenue outlook and said July marked its first month of positive consolidated adjusted free cash flow, including funding provided under its General Catalyst facility.

Prenetics' IM8 Reports Q2 2026 Revenue Growth of 288% YoY; Raises FY 2026 IM8 Revenue Guidance to $220–230 Million; July Was the First Month of Positive Consolidated Adjusted Free Cash Flow and Expected to Remain Positive for Q3 and Beyond

globenewswire.com · 18 Aug 2026

Prenetics' IM8 Reports Q2 2026 Revenue Growth of 288% YoY; Raises FY 2026 IM8 Revenue Guidance to $220–230 Million; July Was the First Month of Positive Consolidated Adjusted Free Cash Flow and Expected to Remain Positive for Q3 and Beyond

Prenetics' IM8 Reports Q2 2026 Revenue Growth of 288% YoY; Raises FY 2026 IM8 Revenue Guidance to $220–230 Million; July Was the First Month of Positive Co

Prenetics, Parent of IM8, Appoints II Ranked, Caroline Levy, Veteran Wall Street Consumer Analyst as Independent Director

globenewswire.com · 17 Aug 2026

Prenetics, Parent of IM8, Appoints II Ranked, Caroline Levy, Veteran Wall Street Consumer Analyst as Independent Director

30+ years as one of Wall Street's top-ranked equity research consumer analysts, including leadership of U.S. consumer research at UBS Caroline will also serve on the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee. Prenetics will report its second quarter 2026 financial results tomorrow, Tuesday, August 18, 2026, and will host a live earnings webcast at 8:30 a.m.

Prenetics to Report Q2 2026 Financial Results on August 18, 2026, Live-Stream Earnings Event on Stocktwits, and Announces Upcoming Conference Participation

globenewswire.com · 7 Aug 2026

Prenetics to Report Q2 2026 Financial Results on August 18, 2026, Live-Stream Earnings Event on Stocktwits, and Announces Upcoming Conference Participation

Prenetics to Report Q2 2026 Financial Results on August 18, 2026, Live-Stream Earnings Event on Stocktwits, and Announces Upcoming Conference Participation

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.